Point72 Middle East FZE’s CorMedix CRMD Stock Holding History

Point72 Middle East FZE’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,477	Closed	-$10.3K	–	1626
2023 Q1	$10.3K	Buy	+2,477	New	+$10.1K	﹤0.01%	1482

Other funds holding CRMD

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Middle East FZE's CRMD Position: Q2 2023 in Review

Point72 Middle East FZE sold out of CorMedix (CRMD) in Q2 2023, closing a stake of 2,477 shares — an estimated $10.3K sold.

Point72 Middle East FZE first reported a position in CRMD in Q1 2023 and held it in 1 quarter. The position peaked at $10.3K in Q1 2023. 86 funds tracked by Wall St. Rank hold CRMD as of Q2 2023.

Point72 Middle East FZE reported no remaining CorMedix position as of Q2 2023 after selling out during the quarter.
Point72 Middle East FZE sold 2,477 CorMedix shares in Q2 2023, an estimated $10.3K.
Point72 Middle East FZE first reported a position in CorMedix in Q1 2023 and held it in 1 quarter.
Point72 Middle East FZE's CorMedix position peaked at $10.3K in Q1 2023.
86 funds tracked by Wall St. Rank held CorMedix as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.